Literature DB >> 26637509

Mepolizumab approved as add-on long-term therapy for severe asthma.

Cheryl A Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26637509     DOI： 10.2146/news150083

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

Review 1.  Targeting NLRP3 Inflammasome Activation in Severe Asthma.

Authors:  Efthymia Theofani; Maria Semitekolou; Ioannis Morianos; Konstantinos Samitas; Georgina Xanthou
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

Review 2.  Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.

Authors:  Rosalia Emma; Jaymin B Morjaria; Virginia Fuochi; Riccardo Polosa; Massimo Caruso
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.